On July 29, CSPC PHARMA rose 3.06% in regular trading, trading at HKD 8.75/share, with turnover of HKD 569 million.

The stock continues to benefit from a cluster of positive developments released over the weekend. On July 27, the company issued a positive profit alert projecting H1 attributable profit of RMB 5.9–6.2 billion, representing over 130% growth versus RMB 2.55 billion in the prior-year period, primarily driven by approximately RMB 5.74 billion in licensing fee revenue recognized in Q2 from an USD 840 million upfront payment. Citibank reiterated a Buy rating with a target price of HKD 11.5, calling the results well above expectations and naming the stock a top pick in the pharma sector.

Additionally, the company announced its novel antidepressant HA1406 met the primary efficacy endpoint in a Phase 3 trial with statistically significant improvement, while its Sirolimus for Injection new drug application was accepted by China's NMPA with breakthrough therapy and priority review designations. These catalysts collectively sustained buying momentum into a second consecutive session of gains.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)